The proceeds from the investment will be used to advance clinical trials in the Company’s current areas of pharmaceutical research and development. "We are pleased to see the
Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated as monotherapy for
GVHD is a condition where the donated bone marrow or peripheral blood stem cells see the recipient’s body as foreign and attack the body. It is a significant
The joint research program is funded through the Global Health Innovative Technology (GHIT) Fund, established for the purpose of promoting research and development of pharmaceutical products, vaccines and
This antibody candidate is now undergoing preclinical development activities in preparation for advancement to clinical trials, with an anticipated IND filing next year. CGEN-15029 is one of multiple
The objective of this pharmacokinetic proof of concept study was to assess two prospective formulations of Hydrocodone DETERx in a bioavailability clinical study. The primary goals were to
The final agreement will be signed, inter alia, subject to the completion of an initial clinical trial in the technology to the satisfaction of Therapix, and the completion
"We selected Theradex to assist the Company in pursuing our proposed studies in Hodgkin’s Lymphoma because of Theradex’s invaluable assistance in finalizing our prior IND with the FDA
As part of the collaboration, Kangstem Biotech will provide iNSCs to ORIG3N for use in its disease-modeling platform. Kangstem Biotech has developed a novel approach to generating patient-specific
This UCART19 clinical trial is sponsored by Servier in close collaboration with Pfizer. The pediatric Phase I is an open label, non-comparative, monocenter study to evaluate the safety
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.